Considerations for controlling the variability of raw biological materials in the manufacturing of autologous patient-specific therapies

Sanjin Zvonic

“...developers should consider seeking solutions to minimize the variability of the raw material driven by the collection practices as early as feasible in the product lifecycle.”

Please enter your email to access content Read now